The Robot Report

  • Home
  • News
  • Technologies
    • Batteries / Power Supplies
    • Cameras / Imaging / Vision
    • Controllers
    • End Effectors
    • Microprocessors / SoCs
    • Motion Control
    • Sensors
    • Soft Robotics
    • Software / Simulation
  • Development
    • Artificial Intelligence
    • Human Robot Interaction / Haptics
    • Mobility / Navigation
    • Research
  • Robots
    • AGVs
    • AMRs
    • Consumer
    • Collaborative Robots
    • Drones
    • Exoskeletons
    • Industrial
    • Self-Driving Vehicles
    • Unmanned Maritime Systems
  • Markets
    • Agriculture
    • Healthcare
    • Logistics
    • Manufacturing
    • Mining
    • Security
  • Financial
    • Investments
    • Mergers & Acquisitions
    • Earnings
  • Resources
    • Careers
    • COVID-19
    • Digital Issues
    • Publications
      • Collaborative Robotics Trends
      • Robotics Business Review
    • RBR50 Winners 2022
    • Search Robotics Database
    • Videos
    • Webinars / Digital Events
  • Events
    • RoboBusiness
    • Robotics Summit & Expo
    • Healthcare Robotics Engineering Forum
    • Field Robotics Engineering Forum
    • DeviceTalks
    • R&D 100
    • Robotics Weeks
  • Podcast
    • Episodes
    • Leave a voicemail

Rani prices $73M IPO for robotic drug-delivery pill

By Brian Buntz | August 4, 2021

Listen to this article
Voiced by Amazon Polly

RaniPill

Rani Therapeutics Holdings, a developer of a robotic drug-delivery pill system, generated $73.3 million in its underwritten initial public offering (IPO) of Class A common stock. The San Jose, Calif.–based company’s IPO of 6.7 million shares priced at $11 a share, generating gross proceeds of $73.3 million.

The company initially targeted an IPO worth approximately $100 million, with shares trading between $14 and $16 on June 30. Shares closed at $10.80 on Aug. 3.

Rani developed a proprietary platform, RaniPill, designed to provide a pill-based alternative to intravenous or subcutaneous administration of biologics. The robotic pill deploys its payload of proteins, peptides or antibodies when it reaches the intestine.

In a Phase 1 trial, the company demonstrated the absorption of a biologic on the order of 65%. “That’s in line with subcutaneous injections, which ranged between 40% and 80%,” said Talat Imran, the company’s CEO. “Based on that and our plans for the rest of the drugs in our pipeline, we felt like it was the right time to go public.”

That study involved Octreotide, a treatment that can reduce excessive growth hormone levels and treat diarrhea linked to some tumors.

The technology is “a robotic pill, but it’s like a chemistry-based robot,” Imran said. Resembling a capsule, albeit larger in size, the robotic capsule has a pH-sensitive coating. The coating keeps the capsule intact as it passes through the stomach when it gets to the small intestines. “When it arrives there, the capsule dissolves and expands a balloon,” Imran said. That occurs as a result of a reaction that is “akin to Alka Seltzer, which produces CO2 gas.” The expansion plays a role in inserting a needle into the intestinal wall.

“There are no sharp pain receptors in the gut,” Imran added. “In our Phase 1, we were able to determine that the patients who were dosed with Rani pills had no sensation or perception when the injection occurred.”

The company has conducted preclinical research on TNFα inhibitors, parathyroid hormone, human growth hormone, GLP-1 and basal insulin.

The appeal of a pill-based alternative to injectables could be especially great for patients on daily subcutaneous medicines such as teriparatide, an osteoporosis treatment often administered daily. The burden of injections limits the therapeutic potential of drugs like teriparatide, Imran said. “We believe that going to an oral formulation could provide more patients with the opportunity to take this medication,” he noted.

Editor’s Note: This article was first published by sister publication Drug Discovery Trends.

Comments

  1. Brenda says

    August 7, 2021 at 10:07 pm

    Interesting

    Reply
  2. Newman says

    August 15, 2021 at 6:16 am

    Adverse effects?

    Reply

Tell Us What You Think! Cancel reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Related Articles Read More >

scan&sand
GrayMatter Robotics’ sanding solution brings in $20M
sprout
Muddy Machines brings in $1.8M for asparagus harvesting robot Sprout
Levita Magnetics raises $26M for Magnetic-Assisted Robotic Surgery platform
The state of robotics investment

2021 Robotics Handbook

The Robot Report Listing Database

Latest Robotics News

Robot Report Podcast

The state of robotics investment
See More >

Sponsored Content

  • Magnetic encoders support the stabilization control of a self-balancing two-wheeled robotic vehicle
  • How to best choose your AGV’s Wheel Drive provider
  • Meet Trey, the autonomous trailer (un)loading forklift
  • Kinova Robotics launches Link 6, the first Canadian industrial collaborative robot
  • Torque sensors help make human/robot collaborations safer for workers

RBR50 Innovation Awards

Leave us a voicemail

The Robot Report
  • Mobile Robot Guide
  • Collaborative Robotics Trends
  • Field Robotics Forum
  • Healthcare Robotics Engineering Forum
  • RoboBusiness Event
  • Robotics Business Review
  • Robotics Summit & Expo
  • About The Robot Report
  • Subscribe
  • Advertising
  • Contact Us

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search The Robot Report

  • Home
  • News
  • Technologies
    • Batteries / Power Supplies
    • Cameras / Imaging / Vision
    • Controllers
    • End Effectors
    • Microprocessors / SoCs
    • Motion Control
    • Sensors
    • Soft Robotics
    • Software / Simulation
  • Development
    • Artificial Intelligence
    • Human Robot Interaction / Haptics
    • Mobility / Navigation
    • Research
  • Robots
    • AGVs
    • AMRs
    • Consumer
    • Collaborative Robots
    • Drones
    • Exoskeletons
    • Industrial
    • Self-Driving Vehicles
    • Unmanned Maritime Systems
  • Markets
    • Agriculture
    • Healthcare
    • Logistics
    • Manufacturing
    • Mining
    • Security
  • Financial
    • Investments
    • Mergers & Acquisitions
    • Earnings
  • Resources
    • Careers
    • COVID-19
    • Digital Issues
    • Publications
      • Collaborative Robotics Trends
      • Robotics Business Review
    • RBR50 Winners 2022
    • Search Robotics Database
    • Videos
    • Webinars / Digital Events
  • Events
    • RoboBusiness
    • Robotics Summit & Expo
    • Healthcare Robotics Engineering Forum
    • Field Robotics Engineering Forum
    • DeviceTalks
    • R&D 100
    • Robotics Weeks
  • Podcast
    • Episodes
    • Leave a voicemail